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Abstract
Introduction: Streptococcus pneumoniae is the most common causative pathogen in community-acquired
pneumonia. Protease-activated receptor-1 (PAR-1) is expressed by multiple cell types present in the lungs and can
be activated by various proteases generated during acute inflammation. The cellular effect of PAR-1 activation
partially depends on the specific protease involved. We here determined the role of PAR-1 in the host response
during murine pneumococcal pneumonia.
Methods: Wild-type (WT) and PAR-1 knockout (KO) mice were infected intranasally with viable S. pneumoniae and
observed in a survival study or euthanized at 6, 24 or 48 hours of infection.
Results: PAR-1 KO mice had a better survival early after infection compared to WT mice. Moreover, PAR-1 KO mice had
lower bacterial loads in lungs and blood at 24 hours and in spleen and liver at 48 hours after infection. This favorable
response was accompanied by lower lung histopathology scores and less neutrophil influx in PAR-1 KO mice.
Conclusion: PAR-1 impairs host defense during murine pneumococcal pneumonia.
Introduction
Streptococcus (S.) pneumoniae or the pneumococcus is
the number one causative pathogen in community-
acquired pneumonia (CAP) [1]. CAP is an important
cause of sepsis: in a recent large sepsis trial 35.6% of the
patients suffered from severe CAP, with the pneumococ-
cus being the most frequent cause [2]. Worldwide
S. pneumoniae is responsible for approximately ten mil-
lion deaths annually, making pneumococcal pneumonia
and sepsis a major health threat [3].
Protease-activated receptors (PARs) are G protein-
coupled receptors that are abundantly expressed in the
lungs [4-6]. PARs, of which four family members have
been described (PAR-1 to -4), carry their own ligand:
proteolytic cleavage leads to exposure of a neo-amino
terminus, which serves as a ligand for the same receptor,
hereby initiating transmembrane signaling. A variety of
proteases can activate PARs, including several proteases
involved in the coagulation system. Intriguingly, activa-
tion of PAR-1 can result in opposite cellular effects
depending on the protease involved in its proteolytic
cleavage: for example high concentrations of thrombin
can cause barrier disruptive effects on vascular endothe-
lium via activation of PAR-1, whereas the anticoagulant
protein activated protein C (APC) exerts barrier protec-
tive and anti-inflammatory effects via the same receptor
[7-9].
We here considered it of interest to investigate the
effect of PAR-1 activation on the course of pneumococcal
pneumonia. Thus far, data on the role of PAR-1 in severe
bacterial infection are limited to studies using endotoxe-
mia or polymicrobial peritonitis induced by cecal ligation
and puncture (CLP) as models of severe sepsis. Kaneider
et al used a pepducin-based approach to show that acti-
vation of PAR-1 is harmful during the early phases of
endotoxemia and CLP-induced sepsis, but beneficial at
later stages [10]. Somewhat contradicting, Niessen et al
showed that PAR-1 is harmful during early as well as late
stages of endotoxemia and sepsis induced by CLP, with a
pivotal role for dendritic cell signaling [11]. We here for
the first time studied the role of PAR-1 in respiratory
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tract infection, using our well-established clinically rele-
vant model of pneumococcal pneumonia, comparing sur-
vival, antibacterial defense and inflammatory responses
in PAR-1 knockout (KO) and normal wild-type (WT)
mice. We show that in pneumococcal pneumonia, PAR-1
impairs host defense, as reflected by a reduced lethality
and lower bacterial loads, lung histopathology scores and
less pulmonary neutrophil influx in PAR-1 KO mice.
Materials and methods
Animals
Heterozygous PAR-1 KO mice on a C57Bl/6 back-
ground were purchased from The Jackson Laboratory
(Bar Harbor, ME, USA) [12]. Animals were intercrossed
to obtain homozygous PAR-1 KO mice. WT C57BL/6
mice were purchased from Charles River (Maastricht,
the Netherlands). All experiments were approved by the
Institutional Animal Care and Use Committee of the
University of Amsterdam.
Experimental infection and sample harvesting
Pneumonia was induced by intranasal inoculation with
approximately 5 × 104 colony-forming units (CFU) of
S. pneumoniae serotype 3 (American Type Culture Collec-
tion, ATCC 6303, Rockville, MD, USA) as described
[13,14]. Mice were sacrificed after 6, 24 or 48 hours of
infection (n = 8 per group per time point) or observed for
4 days in a survival study (n = 14 per group). On prede-
fined time points mice were anesthetized, citrated plasma
was prepared from blood drawn from the vena cava infer-
ior and left lung homogenates were prepared as described
[13,14]. Bacterial loads were determined as described
[13,14]. For further measurements, homogenates were
diluted 1:2 with lysis buffer (300 mM NaCl, 30 mM Tris,
2 mM MgCl2, 2 mM CaCl2, 1% (v/v) Triton X-100,
pH 7.4) with protease inhibitor mix and incubated for
30 minutes on ice, followed by centrifugation at 680 g for
10 minutes. Supernatants were stored at -20ºC until
analysis.
Histology and immunohistochemistry
The right lung was fixed in 10% formalin/PBS for 24 hours
and embedded in paraffin. Sections of 5 µm were cut,
stained with hematoxylin and eosin (H & E) and analyzed
by a pathologist who was blinded for groups as described
[14]. To score lung inflammation and damage, the entire
section was analyzed with respect to the following para-
meters: bronchitis, interstitial inflammation, edema,
endothelialitis, pleuritis and thrombus formation. Each
parameter was graded on a scale of 0 to 4. The total histo-
pathological score was expressed as the sum of the scores.
Granulocyte staining was performed using fluorescein
isothiocyanate-labeled anti-mouse Ly-6G monoclonal
antibody (mAb) (Pharmingen, San Diego, CA, USA) as
described [15,16]. Ly-6G stained slides were photographed
with a microscope equipped with a digital camera (Leica
CTR500, Leica Microsystems, Wetzlar, Germany). Ten
random pictures were taken per slide. Stained areas were
analyzed with Image Pro Plus (Media Cybernetics,
Bethesda, MD, USA) and expressed as percentage of the
total surface area.
Assays
Tumor necrosis factor (TNF)-a, interleukin (IL)-6, IL-10,
IL-12p70, interferon (IFN)-g and monocyte chemoattrac-
tant protein (MCP)-1 were measured by cytometric bead
array (CBA) multiplex assay (BD Biosciences, San Jose,
CA, USA). Macrophage inflammatory protein (MIP)-2
was measured by ELISA (R&D systems, Minneapolis,
MN, USA).
Statistical analysis
Data are expressed as box-and-whisker diagrams depict-
ing the smallest observation, lower quartile, median,
upper quartile and largest observation, as medians with
interquartile ranges or as Kaplan Meier plots. Differences
between groups were determined with Mann-Whitney U
or log rank test where appropriate. Analyses were per-
formed using GraphPad Prism version 4.0 (GraphPad
Software, San Diego, CA, USA). P values less than 0.05
were considered statistically significant.
Results
Survival
To determine whether PAR-1 is important for outcome in
pneumococcal pneumonia a survival study was performed
(Figure 1). PAR-1 KO mice had a significantly delayed
Figure 1 Protease-activated receptor-1 accelerates mortality in
murine pneumococcal pneumonia. Survival of wild-type (dashed
line, open symbols) and protease-activated receptor-1 knockout
(solid line, closed symbols) mice in murine pneumococcal
pneumonia (14 mice per group). * indicates statistical significance as
compared to wild-type (P <0.05, log rank test).
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mortality as compared to WT mice (P <0.05). Median sur-
vival time was 2 days and 21 hours in PAR-1 KO mice as
compared to 2 days and 12 hours in WT mice. Moreover,
at 2 days and 17 hours after infection, 64% of PAR-1 KO
mice was still alive, while only 21% of WT mice had
survived until that time point.
Bacterial outgrowth
To determine whether the difference in survival between
PAR-1 KO and WT mice in pneumococcal pneumonia
could be attributed to a difference in antibacterial defense,
we determined bacterial outgrowth 6, 24 and 48 hours in
lungs, blood and distant organs (spleen, liver) (Figure 2).
At 6 hours after infection, there were no differences in
pulmonary bacterial loads between PAR-1 KO and WT
mice (Figure 2A). At this time point, bacteria could not be
detected in blood and distant organs (Figure 2B to 2D). At
24 hours, PAR-1 KO mice had markedly lower bacterial
burdens in their lungs (Figure 2A) and blood (Figure 2B)
with a trend toward lower levels in spleen (P = 0.18)
(Figure 2C) as compared to WT mice. Whereas at 48
hours the differences in bacterial outgrowth in lung and
blood had subsided (Figure 2A to 2B), PAR-1 KO mice
had lower bacterial loads in spleen (Figure 2C) and liver
(Figure 2D) as compared to WT mice.
Inflammatory response
To investigate the impact of PAR-1 on lung pathology,
we determined histopathology scores of lung tissue slides
obtained 24 and 48 hours after infection. Pneumococcal
pneumonia was associated with pulmonary inflammation
and damage as evidenced by the occurrence of bronchitis,
interstitial inflammation, edema and endothelialitis.
Mean histopathological scores were lower in PAR-1 KO
mice at both 24 and 48 hours after infection (Figure 3A
to 3C). To obtain insight in the role of PAR-1 in neutro-
phil recruitment to the primary site of infection, we per-
formed Ly-6G staining on lung sections at 24 and
48 hours after infection. While there were no significant
differences at 24 hours after infection, PAR-1 KO mice
showed significantly lower neutrophil numbers in lung
tissue later on, as evidenced by lower Ly-6G positivity at
48 hours after infection (Figure 4A to 4C).
To further investigate the role of PAR-1 in the local
inflammatory response, we determined levels of various
cytokines (TNF-a, IL-6, IL-10, IL-12, IFN-g) and che-
mokines (MCP-1, MIP-2) in lung homogenates at 6, 24
and 48 hours after infection (Table 1). During the first
24 hours after infection pulmonary cytokine and chemo-
kine levels did not differ between PAR-1 KO and WT
mice. At 48 hours, lung levels of TNF-a, IL-6 and IFN-g
Figure 2 Lower bacterial outgrowth in protease-activated receptor-1 knockout mice in lungs and blood at 24 hours and in spleen and
liver at 48 hours after induction of murine pneumococcal pneumonia. Bacterial outgrowth in (A) lung, (B) blood, (C) spleen and (D) liver 6,
24, and 48 hours after induction of pneumococcal pneumonia in wild-type (open bars) and protease-activated receptor-1 knockout (grey bars)
mice. Data are expressed as box-and-whisker diagrams depicting the smallest observation, lower quartile, median, upper quartile and largest
observation (eight mice per group). * indicates statistical significance as compared to wild-type (P <0.05, Mann-Whitney U test).
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were considerably higher in PAR-1 KO mice as com-
pared to WT mice (P <0.01 to P <0.05), whereas pul-
monary IL-10, MCP-1 and MIP-2 concentrations did
not differ between groups. IL-12 remained undetectable
in lung homogenates at all time points.
To investigate the role of PAR-1 in the systemic
inflammatory response, we determined levels of the
above mentioned cytokines in plasma (Table 2). At
6 hours after infection, cytokine levels were below detec-
tion (data not shown). At 24 hours after infection, PAR-1
KO mice had substantially lower plasma levels of TNF-a
and MCP-1 (P <0.001) and a trend toward lower IL-6
concentrations (P = 0.08) when compared with WT
mice. These differences had subsided at 48 hours. IL-10,
IL-12 and IFN-g levels stayed below detection throughout
the course of the disease (data not shown).
Discussion
S. pneumoniae is a major cause of morbidity and mortal-
ity in humans and antibiotic resistance in this pathogen
is increasing, which urges the need to study the host
defense mechanisms that influence the outcome of pneu-
mococcal pneumonia and sepsis [1]. In pneumonia and
sepsis PARs are considered to play a pivotal role in the
crosstalk between coagulation and inflammation [4].
Since data on the role of PAR-1 in severe infection are
sparse and the function of PAR-1 in bacterial pneumonia
and sepsis to date is unknown, we here investigated the
involvement of PAR-1 in the host response to pneumo-
coccal pneumonia. We show that PAR-1 hampers anti-
bacterial defense, which is associated with more lung
damage, more lung neutrophil influx and more systemic
inflammation, altogether resulting in a higher mortality.
Previous studies examined the role of PAR-1 in endo-
toxemia and abdominal sepsis induced by CLP, revealing
partially contradicting results [10,11,17]. Our finding that
PAR-1 deficiency improves survival early in severe mur-
ine pneumococcal pneumonia is in accordance with data
by Niessen et al, who, using a PAR-1 antagonist, showed
that functional PAR-1 reduces survival in polymicrobial
sepsis induced by CLP, a finding which was associated
with dendritic cell-mediated sustainment of proinflam-
matory and procoagulant mechanisms [11]. These
authors also showed that PAR-1 KO mice had a better
survival in a 90% lethal dose (LD90) model of endotoxin-

























Figure 3 Lower histopathology scores in protease-activated receptor-1 knockout mice in murine pneumococcal pneumonia.
Representative microphotographs of hematoxylin and eosin stained lung sections, 48 hours after induction of pneumococcal pneumonia in (A)
wild-type and (B) protease-activated receptor-1 knockout mice (100 times original magnification). (C) Total pathology scores 24 and 48 hours
after induction of pneumococcal pneumonia in wild-type (open bars) and protease-activated receptor-1 knockout mice (grey bars). Data are
expressed as box-and-whisker diagrams depicting the smallest observation, lower quartile, median, upper quartile and largest observation (eight
mice per group). * and ** indicate statistical significance as compared to wild-type (P <0.05 and P <0.01 respectively, Mann-Whitney U test).
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earlier study demonstrating an unaltered mortality of
PAR-1 KO mice after a high-dose endotoxin challenge
[17]. In contrast to the studies performed by Niessen and
colleagues [11], the survival benefit of PAR-1 KO mice in
our study was only temporary. This does not necessarily
mean there is no effect of PAR-1 deficiency in later stages
of the disease but could be related to the fact that our
model of severe pneumococcal pneumonia is an LD100
model as opposed to the models used by Niessen et al
[11]. Additional studies using lower infectious doses are
warranted to establish whether PAR-1 deficiency impacts
on survival in less severe pneumonia. Kaneider et al
reported an unaltered survival of PAR-1 KO mice relative
to WT mice in CLP-induced sepsis [10]. However, they
also showed that early treatment with a PAR-1 antagonist
(at t = 0) did improve survival in CLP, whereas adminis-
tration of a PAR-1 agonist at a later time point (t = 4
hours) also conveyed a survival benefit [10]. From their
Table 1 Pulmonary cytokine and chemokine levels in wild-type (WT) and protease-activated receptor-1 (PAR-1 KO)
mice 6, 24 and 48 hours after induction of pneumococcal pneumonia.













TNF-a (pg/ml) 4.45 (3.28-7.10) 5.70 (5.20-7.20) 10.5 (1.30-24.0) 13.0 (3.50-56.1) 27.3 (15.9-40.6) 175 (43.7-215)**
IL-6 (pg/ml) 7.95 (2.50-11.3) 11.6 (10.0-14.7) 227 (23.0-1418) 366 (15.5-1460) 217 (147-382) 770 (397-1642)*
IL-10 (pg/ml) B.D. B.D. 44.3 (34.2-66.6) 34.7 (30.5-39.3) 16.9 (10.0-24.8) 25.1 (16.3-169)
IFN-g (pg/ml) B.D. B.D. 11.7 (9.30-17.4) 13.7 (3.10-34.0) 4.80 (2.90-8.85) 16.7 (11.3-23.2)*
MCP-1 (ng/ml) 0.15 (0.13-0.29) 0.19 (0.12-0.28) 8.38 (4.30-9.93) 5.28 (2.48-7.28) 3.29 (2.88-6.34) 5.69 (2.68-10.1)
MIP-2 (ng/ml) B.D. B.D. 6.89 (3.81-15.9) 12.6 (0.20-37.6) 1.95 (0.77-17.3) 1.14 (1.01-5.05)
Data are medians (interquartile ranges). TNF-a, tumor necrosis factor-a; IL, interleukin; MCP-1, monocyte chemotactic protein-1; MIP-2, macrophage inflammatory























Figure 4 Reduced pulmonary neutrophil influx in protease-activated receptor-1 knockout mice in later stage of murine pneumococcal
pneumonia. Representative slides of lung Ly-6G staining (brown) 24 and 48 hours after induction of pneumococcal pneumonia in (A) wild-type
and (B) protease-activated receptor-1 knockout mice (200 times original magnification). (C) Quantitation of pulmonary Ly-6G 48 hours after
induction of pneumococcal pneumonia in wild-type (open bars) and protease-activated receptor-1 knockout mice (grey bars). Data are
expressed as box-and-whisker diagrams depicting the smallest observation, lower quartile, median, upper quartile and largest observation
(eight mice per group). * indicates statistical significance as compared to wild-type (P <0.05, Mann-Whitney U test).
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studies these investigators concluded that PAR-1 is detri-
mental in early phases of sepsis but beneficial in later
phases, which could explain the absence of a net survival
benefit in PAR-1 KO mice in their studies [10]. A very
recent study identified matrix metalloproteinase (MMP)-
1a as a PAR-1 agonist in mice; blockade of MMP-1a
activity protected against CLP-induced lethality in WT
but not in PAR-1 KO mice, suggesting that MMP-1 acti-
vation of PAR-1 contributes to an adverse outcome of
polymicrobial abdominal sepsis [18]. Clearly, the studies
on the role of PAR-1 endotoxic shock and CLP-induced
sepsis are not fully consistent. We did not evaluate the
effects of pharmacologic blockade of PAR-1 in pneumo-
coccal pneumonia; such studies could reveal potential
time-dependent effects of PAR-1 inhibition and the pos-
sible impact of therapeutic PAR-1 blockade in the con-
text of concurrent antibiotic treatment.
The survival advantage of PAR-1 KO mice in our study
corresponded with lower bacterial loads at various stages
of the infection. In addition, PAR-1 KO mice displayed
lower lung pathology scores and a reduced number of
neutrophils in lung tissue. The mechanisms underlying
these differences remain to be elucidated. Understanding
the role of PAR-1 signaling in infection is difficult due to
the multiple and in part opposite effects ascribed to this
receptor. Indeed, although APC and thrombin can both
activate PAR-1, APC affects the vascular endothelium in
a way that clearly is distinct from thrombin signaling.
Specifically, APC can exert anti-inflammatory, anti-apop-
totic and vasculoprotective signals in endothelial cells via
PAR-1, processes in which the endothelial protein C
receptor plays a pivotal role [7,19], whereas thrombin
induces vascular hyperpermeability via PAR-1 [20]. To
make things more complex, activation of PAR-1 by low
doses of thrombin can (like APC) result in a barrier pro-
tective effect [8], whereas a very recent investigation pro-
vided evidence that activated coagulation factor VII
(FVIIa) can exert a barrier protective effect in endothelial
cells via activation of PAR-1 [21]. Moreover, PAR-1 can
be activated by proteases other than FVIIa, thrombin and
APC, including activated coagulation factor × (FXa),
plasmin, trypsin, cathepsin G, elastase, chymase, and,
as mentioned, MMP-1 [6,18], and multiple cell types
present in the lung express PAR-1, including macro-
phages, mast cells, fibroblasts and airway smooth muscle
cells [6]. Hence, the net effect of PAR-1 activation depends
on the cell types and proteases present during various
stages of the infection. This may also explain the partially
contradictory results obtained on the role of PAR-1 in
CLP-induced abdominal sepsis. Of note, however, in
accordance with our current findings regarding lung
pathology and neutrophil recruitment after infection with
S. pneumoniae, PAR-1 was reported to participate in the
acute lung inflammation elicited by intrapulmonary instil-
lation of bleomycin, as reflected by reduced inflammatory
cell influx in PAR-1 KO mice [22]. This [22] and other
studies [23,24] have further implicated PAR-1 as a proin-
flammatory receptor in acute as well as chronic lung
injury. It was therefore unexpected that PAR-1 KO mice
displayed higher concentrations of the proinflammatory
cytokines TNF-a, IL-6 and IFN-g in lung tissue during
pneumonia. We can only speculate on the mechanism:
theoretically, the increase in cytokine generation in PAR-1
KO mice could be the result of diminished anti-inflamma-
tory endothelial protein C receptor (EPCR-)APC effects
via PAR-1 or to compensatory increases of other proin-
flammatory signaling pathways such as upregulation of
PAR-2 to PAR-4 outweighing the loss of PAR-1 as
a proinflammatory signaling pathway. Further studies are
needed to dissect the exact mechanisms and cell types
at play mediating PAR-1 effects after infection by
S. pneumoniae.
Conclusions
We show that in pneumococcal pneumonia, PAR-1
impairs the host defense response, as reflected by a
reduced lethality, lower bacterial loads, lower lung histo-
pathology scores and less pulmonary neutrophil influx in
PAR-1 KO mice. Considering the complex role of PAR-1
in infection, related to the capacity of multiple proteases
to activate PAR-1 resulting in differential cellular effects
and the multiple cell types expressing PAR-1, this receptor
Table 2 Plasma cytokine and chemokine levels in wild-type (WT) and protease-activated receptor-1 (PAR-1 KO) mice
24 and 48 hours after induction of pneumococcal pneumonia.









TNF-a (pg/ml) 12.2 (11.4-15.4) 7.00 (4.10-9.00)** 13.7 (7.80-30.6) 17.6 (14.1-22.7)
IL-6 (pg/ml) 51.0 (8.58-92.9) 8.10 (2.50-49.8) 58.9 (49.8-210) 51.5 (41.2-69.7)
MCP-1 (ng/ml) 129 (48.6-152) 23.9 (18.7-41.6)** 75.0 (64.7-386) 151 (68.2-191)
Data are medians (interquartile ranges). TNF-a, tumor necrosis factor-a; IL-6, interleukin-6; MCP-1, monocyte chemotactic protein-1. ** indicates statistical
significance compared to wild-type (WT) (P <0.01 respectively, Mann Whitney U test).
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at this moment does not represent a straightforward thera-
peutic target in severe pneumonia and sepsis.
Key messages
• Protease activated receptor (PAR)-1 knock out (KO)
mice have an improved survival as compared to wild-type
(WT) mice in pneumococcal pneumonia.
• PAR-1 KO mice have lower bacterial loads in lungs
and blood at 24 hours and in spleen and liver at 48 hours
after induction of pneumococcal pneumonia as com-
pared to WT mice.
• The favorable response in PAR-1 KO mice with regard
to survival and bacterial outgrowth is accompanied by
lower histopathology scores and less neutrophil influx in
the lungs.
• Taken together, this study shows that PAR-1 hampers
host defense in murine pneumococcal pneumonia.
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